Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

255

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions

Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma

Interventions

BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo urine and blood sample collection

DRUG

Carboplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH